AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Huntington's Disease

Recent research efforts aimed at curing Huntington's Disease.

Last updated

Huntington’s Disease

Overview

Huntington’s disease (HD) is an inherited, progressive brain disorder caused by an expanded CAG DNA repeat in the HTT gene, which leads to production of a harmful form of the huntingtin protein. Each child of a person with the disease has a 50% chance of inheriting the mutation. HD commonly begins in adulthood and causes a changing combination of involuntary movements (chorea), problems with thinking and planning, and psychiatric symptoms such as depression, irritability, or apathy. GeneReviews: Huntington Disease (ncbi.nlm.nih.gov)

HD is ultimately fatal, and there is still no approved treatment shown to stop, reverse, or cure its underlying neurodegeneration. Current care is multidisciplinary and symptom-focused: medicines such as tetrabenazine or deutetrabenazine can reduce disabling chorea, while psychiatric treatment, physical therapy, speech and swallowing support, occupational therapy, nutrition, and social care help preserve safety and quality of life. International Guidelines for the Treatment of Huntington’s Disease (pmc.ncbi.nlm.nih.gov)

Scope of Recent Research (2020–present)

Research since 2020 has been unusually active because HD has a single, known genetic cause and a measurable toxic target—mutant huntingtin (mHTT). The main questions are whether lowering mHTT safely can slow disease, whether preserving normal huntingtin is necessary, how early treatment must begin, and whether blocking ongoing CAG-repeat expansion can prevent later neuronal injury. Several disease-modifying programs are now in human trials, but none has yet demonstrated a cure; the field is closest to establishing whether sustained huntingtin lowering can meaningfully slow progression. Potential disease-modifying therapies for Huntington’s disease (sciencedirect.com)

Major Breakthroughs and Emerging Therapies

The leading strategy is to lower production of huntingtin. uniQure’s AMT-130 (ifezuntirgene inilparvovec) is a one-time brain-delivered gene therapy using an adeno-associated virus type 5 vector to provide a microRNA that lowers both mutant and normal huntingtin. In September 2026, the company reported 48-month follow-up from its Phase I/II program, again comparing treated participants with propensity-score-matched Enroll-HD natural-history controls; these results remain company-reported rather than peer-reviewed and do not establish reversal or cure. AMT-130 48-month update (uniqure.gcs-web.com) The therapy’s potential advantage is durable target lowering after one neurosurgical procedure, but its permanent nature also makes dose selection, brain coverage, immune responses, and long-term safety especially important. AMT-130 Phase I/II program (uniqure.com)

Antisense oligonucleotides (ASOs)—short synthetic strands of nucleic acid that bind RNA—offer a potentially adjustable alternative because they are administered by lumbar puncture and can be stopped. Roche’s tominersen lowers both mutant and normal huntingtin. Its earlier Phase III GENERATION HD1 trial did not show a favorable benefit-risk balance, but the redesigned Phase II GENERATION HD2 study is testing tominersen in people with prodromal or early manifest HD and remained active as of 2026. Tominersen in adults with manifest Huntington’s disease (nejm.org) GENERATION HD2 trial record (clinicaltrials.gov)

A major refinement is allele-selective lowering: reducing the mutant protein while sparing the normal huntingtin protein, which may be biologically important for neurons. Wave Life Sciences’ WVE-003 targeted a genetic marker linked to the mutant HTT copy in a subset of people with HD. In the Phase Ib/IIa SELECT-HD study, the company reported lower cerebrospinal-fluid mHTT with relative preservation of normal huntingtin and no serious adverse events in the small multidose cohort; this was proof of target engagement, not proof of clinical benefit. SELECT-HD Phase Ib/IIa results (ir.wavelifesciences.com) Vico Therapeutics’ VO659 is another intrathecal ASO approach, designed to bind expanded CAG-repeat RNA and preferentially reduce toxic expanded-repeat proteins; its first-in-human Phase I/IIa study includes early manifest HD alongside two spinocerebellar ataxias. VO659 Phase I/IIa trial (clinicaltrials.gov)

Oral small molecules may make repeated, whole-body treatment more practical. PTC Therapeutics’ votoplam (PTC518) modifies HTT messenger-RNA splicing to lower huntingtin production. In May 2025, PTC reported that the Phase II PIVOT-HD trial met its primary endpoint of dose-dependent blood huntingtin lowering at 12 weeks, with exploratory longer-term clinical and biomarker trends; those efficacy observations require confirmation in adequately powered controlled trials. PIVOT-HD Phase II results (ir.ptcbio.com) A more experimental route is gene editing: a 2026 mouse study used in-vivo CRISPR base editing to alter HTT RNA-splicing behavior and reduce mutant huntingtin-associated pathology without creating double-strand DNA breaks. It is an important preclinical advance, but it has not yet been tested in people with HD. In vivo CRISPR base editing for treatment of Huntington’s disease (nature.com)

Clinical Trials and Experimental Approaches

AMT-130 is the most advanced one-time gene-therapy candidate. uniQure submitted a U.S. biologics license application for accelerated approval in October 2026, supported by Phase I/II data and an external Enroll-HD comparison; this is a regulatory submission, not an approval, and the evidence is based on a small treated cohort rather than a conventional large randomized Phase III trial. AMT-130 BLA submission (uniqure.gcs-web.com) The central upcoming question is whether regulators consider the clinical and biomarker evidence sufficiently reliable for accelerated approval and what confirmatory evidence they would require afterward. AMT-130 regulatory plan (uniqure.gcs-web.com)

Other notable programs remain earlier in development. Roche sponsors the active, not recruiting Phase II GENERATION HD2 tominersen trial in prodromal and early manifest HD. GENERATION HD2 trial record (clinicaltrials.gov) PTC’s Phase II PIVOT-HD study tested oral votoplam in Stage 2 and mild Stage 3 HD, while Vico’s recruiting Phase I/IIa VO659 study primarily evaluates safety, tolerability, drug exposure, and biomarker effects. PIVOT-HD protocol (cdn.clinicaltrials.gov) VO659 Phase I/IIa trial (clinicaltrials.gov)

Methodologies and Scientific Approaches

HD researchers combine laboratory models with long-running studies of people who carry the mutation. Candidate therapies are screened in patient-derived cells, rodent models, and nonhuman primates, especially to assess target lowering, unintended effects, and delivery to vulnerable deep-brain regions such as the striatum. For AAV-microRNA therapy, researchers have specifically compared artificial-microRNA processing across cell systems, mice, and nonhuman primates to select designs that lower HTT efficiently without disrupting natural microRNA pathways. Artificial microRNA optimization for Huntington-lowering AAV therapy (pmc.ncbi.nlm.nih.gov)

Trials increasingly use biomarkers alongside symptom scales. These include mutant huntingtin in cerebrospinal fluid, neurofilament light chain (NfL), MRI measures of caudate and putamen volume, and blood measurements of somatic CAG-repeat expansion. The 2022 Huntington’s Disease Integrated Staging System provides a research framework spanning genetic status, measurable brain pathology, clinical signs, and functional decline, helping trials intervene earlier and enroll more comparable participant groups. Huntington’s Disease Integrated Staging System (sciencedirect.com) Evidence published in 2025 linked greater blood CAG-repeat expansion with early brain-biomarker changes and later striatal atrophy, supporting DNA-repeat instability as both a therapeutic target and a possible pharmacodynamic marker. Somatic CAG expansion and early neurodegeneration (nature.com)

Leading Institutions and Funding

The field is driven by a network of academic centers, companies, patient organizations, and data platforms. University College London and collaborating international sites have major roles in clinical trials, biomarker studies, and the HD-ISS framework; CHDI Foundation sponsors Enroll-HD, a global longitudinal observational platform that has enrolled more than 30,000 participants and supplies natural-history data for trial design and external-control analyses. Enroll-HD study record (clinicaltrials.gov) Key industry developers include uniQure, Roche/Genentech, PTC Therapeutics, Wave Life Sciences, Vico Therapeutics, and Skyhawk Therapeutics. Falcon-HD trial record (clinicaltrials.gov)

The U.S. National Institutes of Health remains a major public funder: NIH categorical spending for Huntington’s disease was reported at approximately $39 million in fiscal year 2025, following $44 million in fiscal year 2024. NIH categorical spending: Huntington’s Disease (report.nih.gov) Private disease-focused investment, especially through CHDI, helps fund translational science, shared datasets, and international infrastructure that would be difficult for individual laboratories to sustain. Enroll-HD study record (clinicaltrials.gov)

Strengths, Limitations, and Challenges

HD is unusually well suited to precision medicine because one mutation causes the disease, genetic testing can identify carriers before symptoms, and mutant huntingtin can be measured in cerebrospinal fluid. The emergence of multiple ways to lower huntingtin—ASOs, RNA-splicing drugs, and gene therapy—means the field is no longer dependent on one platform. Evidence that somatic CAG expansion helps drive disease also opens a second, complementary strategy: preventing the mutation from worsening within vulnerable brain cells over time. Somatic CAG expansion and early neurodegeneration (nature.com)

However, lowering a biomarker is not the same as improving a person’s function. The failed GENERATION HD1 trial showed that substantial huntingtin lowering can still have an unfavorable clinical benefit-risk profile. Tominersen in adults with manifest Huntington’s disease (nejm.org) Key unresolved issues include how much mutant huntingtin must be reduced, whether normal huntingtin can safely be lowered in adults, whether treatment must begin before symptoms, whether drugs reach the full range of affected brain regions, and how to interpret small trials that rely on external rather than randomized concurrent controls. Brain surgery and one-time gene therapy also raise access, cost, manufacturing, and irreversible-safety concerns, while intrathecal ASOs require repeated procedures. AMT-130 Phase I/II program (uniqure.com)

Outlook and Future Directions

As of October 18, 2026, HD is not curable, but the field is closer than at any earlier point to determining whether disease progression can be durably slowed through huntingtin lowering. The most important milestones are regulatory review and longer-term follow-up of AMT-130, controlled efficacy results from GENERATION HD2 and subsequent votoplam studies, confirmation that allele-selective agents preserve normal huntingtin while improving clinical outcomes, and the first human translation of approaches that suppress somatic CAG-repeat expansion or edit the disease gene. A true cure would likely require not only preventing further toxic damage but also protecting or restoring already injured neural circuits. In vivo CRISPR base editing for treatment of Huntington’s disease (nature.com)

References

Don't see your disease? Request a report